Objective: We seek to assess Australian psychiatrists' views and practices concerning provision of neuroleptic medication to patients with schizophrenia, and to determine whether such management strategies are likely to have changed over time and the extent to which they correspond to published treatment guidelines.
Method: A sample of 139 psychiatrists based in three Australian capital cities was derived, with respondents completing a brief questionnaire by choosing from a limited-option answer set. Co-authors of this paper comment on the extent to which responses are in line with contemporary recommendations driven by experts or empirical studies.
Results: Overall, survey findings indicate that there has been considerable change in clinical practice over the last decade and provide some estimate of the extent to which Australian management practices are congruent with contemporary recommendations. We identify a number of issues of concern (more in relation to dose levels of neuroleptic medication rather than treatment duration) revealed by survey data and make recommendations for addressing a number of practical clinical issues.
Conclusions: As this report focuses on central issues involved in managing schizophrenia, and integrates a number of treatment guidelines, we suggest that it should be of assistance for practice review by clinicians.
SackettDLRichardsonWSRosenbergWHaynesRBEvidence-based medicine: how to practice and teach EBM. New York: Churchill Livingstone, 1997:72.
2.
EllardJ.The music of psychiatry. Australian and New Zealand Journal of Psychiatry1985; 19:153–156.
3.
The Quality Assurance Project.A treatment outline for depressive disorders. Australian and New Zealand Journal of Psychiatry1983; 17:129–146.
4.
DavisDAThompsonMAOxmanADHaynesRBChanging physician performance. A systematic review of the effect of continuing medical education strategies. Journal of the American Medical Association1995; 274:700–705.
5.
GilbertPLHarrisMJMcAdamsLAJesteDVNeuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry1995; 52:173–188.
6.
JesteDVGilbertPLMcAdamsLAHarrisMJConsidering neuroleptic maintenance and taper on a continuum. Need for longitudinal rather than dogmatic approach. Archives of General Psychiatry1995; 52:209–212.
7.
DavisJMKaneJMMarderSRDose response of prophylactic antipsychotics. Journal of Clinical Psychiatry1993; 54(Suppl.):24–30.
8.
LetemendiaFJHarrisADWillemsPJThe clinical effects on a population of chronic schizophrenic patients of administrative changes in hospitals. British Journal of Psychiatry1967; 113:959–971.
9.
HirschSRGaindRRohdePDStevensBCWingJKOutpatient maintenance of chronic schizophrenic patients with long acting fluphenazine: a double-blind placebo trial. British Medical Journal1973; 1:633–637.
10.
HogartyGEUlrichRFTemporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry1997; 34:297–301.
11.
MieseUFleishakerW.Perceptions on treatment needs in schizophrenia. British Journal of Psychiatry1996; 168(Suppl. 29):9–16.
12.
American Psychiatric Association.Tardive dyskinesia. A task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992.
13.
LoebelADLeibermanJAAlvirJMMayerhoffDIGeislerSHSzymanskiSRDuration of psychosis and outcome in first-episode schizophrenia. American Journal of Psychiatry1992; 149:1183–1188.
14.
McEvoyJPHogartyGESteingardS.Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry1991; 48:739–745.
15.
KopalaLCFredriksonDGoodKPHonerWGSymptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Biological Psychiatry1996; 39:296–298.
16.
American Psychiatric Association.Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry1997; 154(Suppl. 4):1–61.
17.
The Quality Assurance Project 1984.Treatment outlines for the management of schizophrenia. Australian and New Zealand Journal of Psychiatry1984; 18:19–38.
18.
Steering Committee, American Psychiatric Association.The Expert Consensus Guideline Series. Treatment of schizophrenia. Journal of Clinical Psychiatry1996; 57(Suppl. 12b): 1–59.
19.
WhiteP.Identification of randomised clinical trials in the Australian and New Zealand Journal of Psychiatry for the Cochrane Collaboration. Australian and New Zealand Journal of Psychiatry1996; 30:531–533.